Skip to main content
Premium Trial:

Request an Annual Quote

Doug Farrell, David Block

Premium

Affymetrix has appointed Doug Farrell as its new vice president of investor relations. Farrell comes to Affymetrix from Aurora Biosciences, where he served as senior director of investor relations and corporate communications. Aurora was acquired by Vertex Pharmaceuticals in July.

 

David Block has been appointed executive vice president of Celera, and chief operating officer of Celera’s therapeutics business. Block comes to Celera from DuPont Pharmaceuticals, where he worked for 12 years, most recently serving as executive vice president for international operations.

At Celera, Block will oversee the development of its pharmaceutical business, coordinating the therapeutic program, and will oversee mergers and acquisitions, as well as directing alliances and licensing agreements with other companies.

Block replaces Peter Barrett, a co-founder of Celera who served as chief business officer and executive vice president. Barrett has accepted a position at Atlas Venture, a leading life sciences venture capital firm. Barrett will work with Jean-Francois Formela out of Atlas’ Boston office to lead investments in US life sciences companies.

Before founding Celera, Barrett moved PerkinElmer into life sciences, shepherding its acquisition of Applied Biosystems in 1993.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more